ST
SERDA Therapeutics develops a proteolytic enzyme-based wound debridement solution that selectively digests necrotic tissue and eschar, facilitating faster healing of severe burn injuries and chronic ulcers. This targeted approach addresses the challenges of traditional debridement methods, which are often painful, ineffective, and costly.
Updated 20 months ago
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- SERDA Therapeutics develops a proteolytic enzyme-based wound debridement solution that selectively digests necrotic tissue and eschar, facilitating faster healing of severe burn injuries and chronic ulcers. This targeted approach addresses the challenges of traditional debridement methods, which are often painful, ineffective, and costly.